Imidazole: Synthesis, Functionalization and Physicochemical Properties of a Privileged Structure in Medicinal Chemistry
Imidazole was first synthesized by Heinrich Debus in 1858 and was obtained by the reaction of glyoxal and formaldehyde in ammonia, initially called glyoxaline. The current literature provides much information about the synthesis, functionalization, physicochemical characteristics and biological role of imidazole. Imidazole is a structure that, despite being small, has a unique chemical complexity. It is a nucleus that is very practical and versatile in its construction/functionalization and can be considered a rich source of chemical diversity. Imidazole acts in extremely important processes for the maintenance of living organisms, such as catalysis in enzymatic processes. Imidazole-based compounds with antibacterial, anti-inflammatory, antidiabetic, antiparasitic, antituberculosis, antifungal, antioxidant, antitumor, antimalarial, anticancer, antidepressant and many others make up the therapeutic arsenal and new bioactive compounds proposed in the most diverse works. The interest and importance of imidazole-containing analogs in the field of medicinal chemistry is remarkable, and the understanding from the development of the first blockbuster drug cimetidine explores all the chemical and biological concepts of imidazole in the context of research and development of new drugs.
Top-30
Journals
|
1
2
3
4
5
|
|
|
ChemistrySelect
5 publications, 4.55%
|
|
|
Scientific Reports
5 publications, 4.55%
|
|
|
Journal of Molecular Structure
5 publications, 4.55%
|
|
|
Pharmaceutics
4 publications, 3.64%
|
|
|
Molecules
4 publications, 3.64%
|
|
|
Chemistry
2 publications, 1.82%
|
|
|
Chemistry - A European Journal
2 publications, 1.82%
|
|
|
Current Organic Chemistry
2 publications, 1.82%
|
|
|
Organic and Biomolecular Chemistry
2 publications, 1.82%
|
|
|
Polyhedron
2 publications, 1.82%
|
|
|
Journal of Organic Chemistry
2 publications, 1.82%
|
|
|
Synthetic Communications
2 publications, 1.82%
|
|
|
Crystal Growth and Design
1 publication, 0.91%
|
|
|
Plants
1 publication, 0.91%
|
|
|
MolBank
1 publication, 0.91%
|
|
|
Arabian Journal of Chemistry
1 publication, 0.91%
|
|
|
Antioxidants
1 publication, 0.91%
|
|
|
International Journal of Biological Macromolecules
1 publication, 0.91%
|
|
|
Future Medicinal Chemistry
1 publication, 0.91%
|
|
|
Structural Chemistry
1 publication, 0.91%
|
|
|
Frontiers in Medicine
1 publication, 0.91%
|
|
|
Heliyon
1 publication, 0.91%
|
|
|
Algal Research
1 publication, 0.91%
|
|
|
Synthetic Metals
1 publication, 0.91%
|
|
|
Chemical Communications
1 publication, 0.91%
|
|
|
Mediators of Inflammation
1 publication, 0.91%
|
|
|
Bioorganic and Medicinal Chemistry
1 publication, 0.91%
|
|
|
Frontiers in Immunology
1 publication, 0.91%
|
|
|
Synthesis
1 publication, 0.91%
|
|
|
Chinese Journal of Chemistry
1 publication, 0.91%
|
|
|
1
2
3
4
5
|
Publishers
|
5
10
15
20
25
30
|
|
|
Elsevier
27 publications, 24.55%
|
|
|
Wiley
19 publications, 17.27%
|
|
|
Springer Nature
16 publications, 14.55%
|
|
|
MDPI
14 publications, 12.73%
|
|
|
Royal Society of Chemistry (RSC)
8 publications, 7.27%
|
|
|
American Chemical Society (ACS)
5 publications, 4.55%
|
|
|
Taylor & Francis
4 publications, 3.64%
|
|
|
Bentham Science Publishers Ltd.
4 publications, 3.64%
|
|
|
Frontiers Media S.A.
3 publications, 2.73%
|
|
|
King Saud University
1 publication, 0.91%
|
|
|
Hindawi Limited
1 publication, 0.91%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.91%
|
|
|
Shanghai Institute of Organic Chemistry
1 publication, 0.91%
|
|
|
International Union of Crystallography (IUCr)
1 publication, 0.91%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.91%
|
|
|
Pleiades Publishing
1 publication, 0.91%
|
|
|
Turkish Chemical Society
1 publication, 0.91%
|
|
|
A and V Publications
1 publication, 0.91%
|
|
|
Ural Federal University
1 publication, 0.91%
|
|
|
5
10
15
20
25
30
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.